Are nanotechnological approaches the future of treating inflammatory diseases?
anti-inflammatory drugs
chronic inflammation
immunosuppressive treatments
mononuclear phagocytic system
nanoparticles
phagocytes
tolerance
Journal
Nanomedicine (London, England)
ISSN: 1748-6963
Titre abrégé: Nanomedicine (Lond)
Pays: England
ID NLM: 101278111
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
16
8
2019
medline:
28
7
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
The current treatments for chronic inflammatory diseases cause severe side effects due to nonspecific drug accumulation. Nanotechnology opens the way to new therapeutic strategies that exploit the ability of immune cells, and especially of phagocytes, to internalize nanoparticles. The cellular uptake of nanoparticles requires specific interactions and is affected by the chemical and physical properties of the carriers. Therefore, optimizing these properties is crucial for designing nanodrugs for immunotherapy. In perspective, we discuss the nanoparticle-based approaches that have been proposed to induce tolerance in autoimmune disorders and lessen the symptoms of inflammatory diseases.
Identifiants
pubmed: 31414616
doi: 10.2217/nnm-2019-0159
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM